CGS : Patents & Other IP

Patents & Other IP : Displaying 208-217 of 276

Who will benefit more, consumers or drug firms? [California]by Steve Johnson, San Jose Mercury NewsSeptember 29th, 2005A consumer watchdog group has revealed that 13 of the 16 institutions to receive the first round of grants from California's stem cell research program have ties to major biomedical companies.

Stem cell_s shell game?Capitol WeeklySeptember 22nd, 2005"The biggest question surrounding stem cell research in California right now isn_t whether it will eventually cure devastating health problems. It_s what happened to the billion dollars."

Stem cell research: cutting-edge science or corporate subsidies, courtesy of voters?[Quotes CGS's Marcy Darnovsky]Capitol WeeklySeptember 15th, 2005Malcolm Maclachlan of the Capitol Weekly reviews the public interest criticism of the CIRM, focusing on the intellectual property issues.

Stem cell grants, minus cash, on tapby Laura Mecoy, Sacramento BeeSeptember 8th, 2005The governing board of California's stem cell program plans to announce the recipients of its first round of grants tomorrow, even though there is no money to distribute.

Letter from CGS to the CIRM Independent Citizens Oversight Committeeby Jesse Reynolds and Marcy DarnovskySeptember 8th, 2005

Editorial: Stem cell funding is venture capitalSan Francisco ExaminerAugust 30th, 2005"Prop. 71's $3 billion in public money was not meant to be a gift. It was meant to be an investment made with the reasonable expectation that funds fronted to the industry now will yield some quantifiable dividend in the future."

Editorial: Stem cell propertySacramento BeeAugust 29th, 2005"California needs to have some measure of control over the intellectual property it has agreed to finance.... [balancing] the public interest with the realities that California is competing against other countries to advance stem cell research."

Report finds stem cell windfall assumptions unrealisticby Terri Somers, San Diego Union-TribuneAugust 25th, 2005"Expectations of huge financial and medical returns on California's $3 billion investment in stem cell research are unrealistic and based on overblown analysis, according to a study by a panel of research, business and academic professionals."

Stem Cell Intellectual Property Report Fails to Protect California's InterestCommittee does not include state or public interest, says the Center for Genetics and SocietyAugust 23rd, 2005

Editorial: Agency in denial - Stem cell board lacks money, not issues [California]Sacramento BeeAugust 13th, 2005The leadership of the California stem cell program should use the delay due to litigation "by settling issues that will continue to dog the institute over the next decade." Instead, it's promising grants before there's money, and signing no-bid contracts.

Displaying 208-217 of 276
< Prev Next >>
« First Page Last Page »
« Show Complete List »

ESPAÑOL | PORTUGUÊS | Русский